The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy

The residual cancer burden index (RCB) was proposed as a response evaluation criterion in breast cancer patients treated with Neoadjuvant Chemotherapy (NAC). This study evaluated the relevance of RCB with replase-free survival (RFS).